Pharm2Farm reported on Thursday the availability of the Pro-Larva mask that integrates the unique British technology based on copper nanoparticles to create an effective virucidal barrier against Covid-19 and other types of viruses, including the flu virus.
The company added that the Pro-Larva mask is the new antiviral mask that kills 99.9% of Covid-19 in the first five minutes of contact. The new revolutionary device, unlike the traditional masks, offers an unsurpassed level of protection against viruses, not only for those around the wearer but also for the wearer.
According to the company, the Pro-Larva mask is designed for hospitals, retirement homes, schools, retail and leisure sectors.
A spin out from Nottingham Trent University, Pharm2Farm Ltd produces and sells these masks through an exclusive license from NTU.
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system
Bonesupport shifts CERAMENT V review to FDA's De Novo pathway
Neola Medical secures US patent for disposable lung monitoring probes
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance